A review of predictive, prognostic and diagnostic biomarkers for non-small-cell lung cancer: towards personalised and targeted cancer therapy

被引:4
|
作者
Osei, Ernest [1 ,2 ,3 ,4 ]
Lumini, Julia [5 ]
Gunasekara, Dinindu [2 ]
Osei, Beverley [6 ]
Asare, Akua [7 ]
Laflamme, Raymond [8 ]
机构
[1] Grand River Reg Canc Ctr, Dept Med Phys, Kitchener, ON, Canada
[2] Univ Waterloo, Dept Phys & Astron, Waterloo, ON, Canada
[3] Univ Waterloo, Dept Syst Design Engn, Waterloo, ON, Canada
[4] Univ Guelph, Dept Clin Studies, Ontario Vet Coll, Guelph, ON, Canada
[5] Univ Waterloo, Dept Biol, Waterloo, ON, Canada
[6] McMaster Univ, Dept Hlth Sci, Hamilton, ON, Canada
[7] Brock Univ, Dept Gen Sci, St Catharines, ON, Canada
[8] Univ Waterloo, Inst Quantum Comp, Waterloo, ON, Canada
关键词
cancer therapy; chromosome aberration; genes biomarkers; non-small-cell lung cancer; protein biomarkers; CLINICALLY SELECTED PATIENTS; ANAPLASTIC LYMPHOMA KINASE; PI3K PATHWAY; OPEN-LABEL; RESISTANCE MUTATION; ACQUIRED-RESISTANCE; GEFITINIB TREATMENT; MEK INHIBITORS; EARLY-STAGE; PHASE-III;
D O I
10.1017/S1460396919000876
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Introduction: Lung cancer has a high mortality rate mainly due to the lack of early detection or outward signs and symptoms, thereby often progressing to advanced stages (e.g., stage IV) before it is diagnosed. However, if lung cancers can be diagnosed at an early stage and also if clinicians can prospectively identify patients likely to respond to specific treatments, then there is a very high potential to increase patients' survival. In recent years, several investigations have been conducted to identify cancer biomarkers for lung cancer risk assessment, early detection and diagnosis, the likelihood of identifying the group of patients who will benefit from a particular treatment and monitoring patient response to treatment. Materials and Methods: This paper reports on the review of 19 current clinical and emerging biomarkers used in risk assessment, screening for early detection and diagnosis and monitoring the response of treatment of non-small-cell lung cancers. Conclusion: The future holds promise for personalised and targeted medicine from prevention, diagnosis to treatment, which take into account individual patient's variability, though it depends on the development of effective biomarkers interrogating the key aberrant pathways and potentially targetable with molecular targeted or immunologic therapies. Lung cancer biomarkers have the potential to guide clinical decision-making since they can potentially detect the disease early, measure the risk of developing the disease and the risk of progression, provide accurate information of patient response to a specific treatment and are capable of informing clinicians about the likely outcome of a cancer diagnosis independent of the treatment received. Moreover, lung cancer biomarkers are increasingly linked to specific molecular pathway deregulations and/or cancer pathogenesis and can be used to justify the application of certain therapeutic or interventional strategies.
引用
收藏
页码:370 / 384
页数:15
相关论文
共 50 条
  • [1] A review of predictive, prognostic and diagnostic biomarkers for brain tumours: towards personalised and targeted cancer therapy
    Osei, Ernest
    Walters, Pascale
    Masella, Olivia
    Tennant, Quinton
    Fishwick, Amber
    Dadzie, Eugenia
    Bhangu, Anmol
    Darko, Johnson
    JOURNAL OF RADIOTHERAPY IN PRACTICE, 2021, 20 (01) : 83 - 98
  • [2] Targeted therapy for localized non-small-cell lung cancer: a review
    Paleiron, Nicolas
    Bylicki, Olivier
    Andre, Michel
    Riviere, Emilie
    Grassin, Frederic
    Robinet, Gilles
    Chouaid, Christos
    ONCOTARGETS AND THERAPY, 2016, 9 : 4099 - 4104
  • [3] Targeted therapy for non-small-cell lung cancer
    Rasul, K. T.
    Al-Khater, A. M.
    JOURNAL OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH, 2010, 40 (03): : 221 - 221
  • [4] Targeted therapy for non-small-cell lung cancer
    Belani, CP
    LUNG CANCER, 2004, 45 : S7 - S7
  • [5] Targeted therapy in non-small-cell lung cancer
    Herbst, RS
    ONCOLOGY-NEW YORK, 2002, 16 (09): : 19 - 24
  • [6] Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer A Review
    Wood, Kevin
    Hensing, Thomas
    Malik, Raeva
    Salgia, Ravi
    JAMA ONCOLOGY, 2016, 2 (06) : 805 - 812
  • [7] Clinical outcomes in non-small-cell lung cancer in relation to expression of predictive and prognostic biomarkers
    Singh, Navneet
    Bal, Amanjit
    Aggarwal, Ashutosh N.
    Das, Ashim
    Behera, Digambar
    FUTURE ONCOLOGY, 2010, 6 (05) : 741 - 767
  • [8] Targeted therapy in advanced non-small-cell lung cancer
    Gettinger, Scott
    SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2008, 29 (03) : 291 - 301
  • [9] Diagnostic, Predictive, and Prognostic Biomarkers in Non-Small Cell Lung Cancer (NSCLC) Management
    Sutic, Maja
    Vukic, Ana
    Baranasic, Jurica
    Foersti, Asta
    Dzubur, Feda
    Samarzija, Miroslav
    Jakopovic, Marko
    Brcic, Luka
    Knezevic, Jelena
    JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (11):
  • [10] The Role of the Selected miRNAs as Diagnostic, Predictive and Prognostic Markers in Non-Small-Cell Lung Cancer
    Szczyrek, Michal
    Bitkowska, Paulina
    Jutrzenka, Marta
    Milanowski, Janusz
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (08):